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Abstract 
The development of drugs that can inactivate disease-causing cells (e.g. cancer cells or parasites) 
without causing collateral damage to healthy or to host cells is complicated by the fact that many 
proteins are very similar between organisms. Nevertheless, due to subtle, quantitative differences 
between the biochemical reaction networks of target cell and host, a drug can limit the flux of the 
same essential process in one organism more than in another. We identified precise criteria for this 
‘network-based’ drug selectivity, which can serve as an alternative or additive to structural 
differences. We combined computational and experimental approaches to compare energy 
metabolism in the causative agent of sleeping sickness, Trypanosoma brucei, with that of human 
erythrocytes, and identified glucose transport and glyceraldehyde-3-phosphate dehydrogenase as 
the most selective antiparasitic targets. Computational predictions were validated experimentally in 
a novel  parasite-erythrocytes co-culture system. Glucose-transport inhibitors killed trypanosomes 
without killing erythrocytes, neurons or liver cells. 
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Introduction 
In the treatment of both cancer and infectious diseases, the major challenge is to design selective 
drugs that target the cancer cell or pathogen without harming the patient. Indeed, two main reasons 
for the failure of candidate drugs at a late stage are lack of a therapeutic effect and problems with 
drug safety 1, 2, 3. Classically, drug-design strategies are aimed at a molecular target that is both 
essential and unique to the diseased cell. Often such choices are limited, however. For instance, 
cancer cells originate from healthy cells and their genomes are virtually identical to those of healthy 
cells. Therefore, unique cancer proteins are rare. Analogously, eukaryotic pathogens tend to be 
biochemically similar to some cells of the host. In such cases we may need to drop the criterion of 
uniqueness and seriously consider drug targets that are part of pathways that also occur in the host 
and that may even be essential there.  
Pathogen proliferation and survival depend on metabolism for the supply of free energy and 
molecular building blocks. This makes metabolic enzymes attractive drug targets. Of course,  a 
putative target enzyme should be essential for pathogen survival. Researchers assess this 
experimentally through gene knockouts or computationally using genome-scale metabolic models 4. 
Comparative computational analysis of constraint-based models allows the identification of targets 
that are essential for the pathogen but not for the host5. At safe doses, however, inhibitors rarely 
cause 100% inhibition. The resulting residual enzyme activity makes chemical inhibition essentially 
different from a gene knockout, as is implicitly acknowledged by the use of IC50 rather than IC100 
values for drug efficacy. This means that when identifying effective drug targets we must consider 
additional criteria besides essentiality. 
The overall effect of an enzyme inhibitor on cell function depends on multiple factors. Classically, the 
focus is on the efficiency of inhibitor uptake by the cell and on the binding affinity of inhibitors for 
their target enzyme. These factors may be optimized by altering the chemical structure of inhibitors, 
resulting in structure-based drug selectivity (see e.g. 6). In vivo, however, two other important factors 
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must be taken into consideration. First, the direct effect of the inhibitor on enzyme activity also 
depends on concentrations of intracellular metabolites that act on the target enzyme. Thus, 
competitive inhibitors may be competed away by rising substrate concentrations, while 
uncompetitive inhibitors become more effective at high substrate concentrations 7. Second, the 
control exerted on cell function (i.e. the extent to which an enzyme is rate-limiting) differs 
considerably between putative target enzymes, and even between sequential and essential enzymes 
in a single metabolic pathway (e.g. 8). Some very important enzymes are present in excess and need 
to be inhibited almost completely before cell function is affected, while others are present in limiting 
amounts9. These two factors – interacting metabolite concentrations and the target enzyme’s degree 
of control over cell function – depend on the kinetic properties of the metabolic network as a whole 
and are important for the efficacy and selectivity of drugs in vivo. These network properties should 
therefore be included when ranking putative drug targets. They constitute the basis for network-
based drug selectivity.  
In this study, we developed the concept of network-based drug selectivity and applied it to glycolysis 
in Trypanosoma brucei – the parasite that causes African sleeping sickness – and glycolysis in the 
erythrocytes of its human host. We aimed to identify targets that are essential in both organisms but 
– when inhibited – target the parasite more effectively than the erythrocytes. Sleeping sickness is a 
deadly infectious disease for which new drugs are urgently needed. Current drugs have limited 
effectiveness, are highly toxic, and are experiencing rapidly increasing resistance 10. Older drugs, such 
as suramin and melarsoprol have multiple targets, among which metabolic enzymes 11. Eflornithine, a 
relatively recent drug, targets ornithine decarboxylase, an enzyme within the polyamine synthesis 
pathway 11. T. brucei is a eukaryotic parasite that is transferred between mammals by bites of the 
tsetse fly. Before it eventually enters the central nervous system, the parasite proliferates 
extracellularly in the mammalian bloodstream. During this stage of its lifecycle, glycolysis is essential 
for survival as it is the only source of ATP. Only 50% inhibition of glycolysis is sufficient to kill 
trypanosomes 12, which makes it a potent target pathway for antitrypanosomal drugs. Structural 
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differences between human and trypanosome glycolytic enzymes make some of them attractive as 
drug targets  13. Nevertheless, since glycolysis is also vital for the human host’s cells, drug selectivity 
remains a critical challenge. Notably, the erythrocytes that co-localize with T. brucei in the 
bloodstream also depend exclusively on glycolysis for their ATP and all their glycolytic enzymes are 
essential. Insufficient drug selectivity might therefore result in anemia 14. These aspects make 
erythrocytes well-suited for testing the validity of the concept of network-based drug target 
identification. 
We here analyzed two validated, data-driven kinetic models of glucose metabolism, one of the 
clinically relevant long-slender bloodstream stage of T. brucei and the other of human erythrocytes 15, 
16. We quantified the network-based efficacy and selectivity of its enzymes as drug targets. 
Subsequently, we proved theoretically that the network-based component of drug selectivity is 
equally important as its structure-based component. Finally, we experimentally validated one of the 
most highly ranked drug targets: the plasma membrane glucose transporter. We showed in specially 
designed co-culture experiments of trypanosomes and erythrocytes that glucose-transport inhibitors 
do not need structural selectivity to target parasite metabolism and survival selectively. Finally, 
mammalian neuronal cells and hepatocytes were much less affected by such inhibitors than 
trypanosomes or malaria-infected erythrocytes. 
 
Results 
Ranking drug targets by kinetic modelling 
To identify potent, network-selective drug targets, we used two equally detailed computer models of  
glycolysis, one for T. brucei 15 and one for the human erythrocyte 16. The common glycolytic pathway 
with cell-type specific differences is schematically depicted in Fig. 1a. For each of the glycolytic 
enzymes in this pathway, we simulated the effect of competitive inhibitors (Fig 1b). Both computer 
models consist of ordinary differential equations that describe how metabolite concentrations 
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change over time. In these models the enzyme rates depend on the concentrations of substrates, 
products and effectors. The models contain mechanism-based enzyme-kinetic rate laws and have 
experimentally determined parameters. We used the models in the steady-state mode, when 
concentrations and fluxes have reached a time-independent, stable state. First, we investigated the 
effect of competitive inhibitors, since they represent the majority of existing mechanism- and 
structure-based inhibitors 17.  
A competitive inhibitor I affects an enzyme through its Michaelis-Menten constant (Km) for the 
competing substrate and  product according to the formula  
ܭ௠ሺ[ܫ]/ܭ௜ሻ = ܭ௠ሺ0ሻ ∙ ሺ1 + [ܫ]/ܭ௜ሻ       (Eq. 1) 
Here Ki is the inhibition constant of the inhibitor for the enzyme and Km(0) is the Km in the absence of 
the inhibitor. An [I]/Ki of 1 effectively doubles the Km for the specific competing substrate, which 
means a 33% reduction in enzyme activity at half-saturating substrate concentration. The lower the 
Ki, the stronger the inhibitor affects the enzyme. The Ki depends on the structural affinity of the 
inhibitor for the active site of the enzyme. Varying the [I]/Ki ratio rather than the inhibitor 
concentration itself ensures that the simulations are independent of this structural affinity and hence 
independent of the actual inhibitor used.  
Antitrypanosomal drugs that target glycolysis should in the first place exert a strong effect on the 
ATP production flux, which is exclusively glycolytic in the trypanosome. The effect of inhibitors on the 
T. brucei ATP production flux depended strongly on their target enzyme: e.g. an inhibitor of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or glucose transport reduced the ATP 
synthesis flux more than an inhibitor of hexokinase, which in turn was more effective than an enolase 
inhibitor (Fig. 1C). We used these titrations to calculate – for each combination of enzyme and 
competing substrate/product – which [I]/Ki was required to reduce the T. brucei ATP production flux 
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by 90% (Fig. 1c) and sorted them from lowest to highest (Fig. 1d). The lower the [I]/Ki ratio needed 
for 90% inhibition of glycolytic flux, the lower the dose that will be required to kill the parasites and 
thus the more potent the target. The 90% cut-off is a safe choice, since already 50% inhibition is 
sufficient to start killing trypanosomes 12. Qualitatively, the ranking was hardly affected by the 
precise cut-off, as can also be seen from the complete titration curves (Fig 2 and Supplementary Fig 
S1).  For inhibitors of GAPDH – which compete with the enzyme’s substrate glyceraldehyde 3-
phosphate (GAP) and with its product 1,3-bisphosphoglycerate (13BPGA) – a concentration of 35 
times the Ki was sufficient to reduce the flux by 90%. In contrast, a competitive inhibitor of enolase 
required a dose of more than 106 times its Ki to achieve the same effect. For some enzymes with 
multiple substrates the choice of the competing substrate affected the outcome: an inhibitor of 
pyruvate kinase (PYK) that competed with ADP and ATP achieved 90% flux inhibition at a markedly 
lower concentration than one that competed with phosphoenolpyruvate (PEP) and pyruvate (Fig. 
1d). According to our predictions, the three best competitive inhibitors acted either on GAPDH 
(competitive with either GAP/13BPGA or NAD+/NADH) or on the glucose transporter in the plasma 
membrane (GlcT). 
To avoid toxicity, putative drugs should have minimal effect on erythrocyte glycolysis. We therefore 
used the same competitive inhibitors for titrations in the erythrocyte model and the trypanosome 
model (Figs. 2a-d and supplementary Fig. S1). Inhibition of the most potent targets in T. brucei – 
GAPDH and glucose transport – had only a limited effect on erythrocyte glycolysis (Fig. 2a-c), 
classifying them as highly selective network-based targets. The next most potent T. brucei inhibitor – 
acting on phosphofructokinase (PFK) and competitive with fructose 6-phosphate (Fig. 1d) – conferred 
unwanted network selectivity: a greater effect on erythrocyte glycolysis than on trypanosome 
glycolysis (Fig. 2d). For the [I]/Ki values that inhibited 90% of the T. brucei glycolytic flux (Fig. 1d) we 
calculated how the flux would be affected in erythrocytes (Fig. 2e). This confirmed that the three 
competitive inhibitors that were most effective in reducing T. brucei flux (the two GAPDH inhibitors 
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and the GlcT inhibitor) did not affect erythrocyte flux. There were three other inhibitors that had 
moderate or negligible effects on erythrocyte glycolysis. However, for these inhibitors, 10- to 1000-
fold higher doses (or lower Ki) are needed to inhibit the trypanosome flux by 90% (cf. Fig. 1d), making 
them less suitable as potential drugs. 
Network-based selectivity is just as important as structure and pharmacokinetics for the overall drug 
selectivity 
We then studied the general principles underlying drug selectivity by adopting the framework of 
metabolic control analysis (MCA) (reviewed in 18). The overall effect of a drug on cell function 
depends on: (i) the drug concentration to which the target enzyme is exposed, and which depends on 
pharmacokinetics; (ii) the structural affinity of the target enzyme for the drug; (iii) the local 
environment of the enzyme (e.g. competing metabolite concentrations) which affects the in vivo 
affinity of the target enzyme to the drug; and finally (iv) to which extent the target enzyme limits a 
vital metabolic process. MCA addresses perturbations in the mathematical limit to infinitely small 
parameter changes and provides therefore an approximation of real drug effects. The advantage is 
that we can apply it to integrate network-based and structure-based selectivitiy in general, 
mathematical terms. In MCA the effect of a small change in inhibitor concentration d[I]T at the target 
site on a steady-state metabolic flux J is approximated by a response coefficient ܴ[ூ]೅
௃ . Here we use a 
partially normalized version of the response coefficient, to avoid division by zero at zero [I]T: 
ܴ	∗ [ூ]೅
௃ ≡ ௗ௃/௃ௗ[ூ]೅, which can be dissected into: 
*ܴ[ூ]೅
௃ = ௗ௃/௃ௗ௩೔/௩೔ ∙
డ௩೔/௩೔
డ[ூ]೅     (Eq. 2) 
in which vi is the rate of enzyme i; and where the partial derivative ∂ is taken by only changing the 
concentration of the inhibitor at constant values of metabolite concentrations. The total derivative 
indicated by the d’s refers to the effect of the altered enzyme rate vi on the flux J through both direct 
and indirect effects. 
Using the flux control coefficient: 
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ܥ௜௃ ≡ ௗ௃/௃ௗ௩೔/௩೔          (Eq. 3) 
and the partially normalized elasticity coefficient: 
ߝ	∗ [ூ]೅/௄೔௜ ≡
డ௩೔/௩೔
డ[ூ]೅/௄೔         (Eq. 4) 
we rewrite equation 2 into: 
݀ܬ ܬ⁄ = 	 ܴ	∗ [ூ]೅
௃ ∙ 	݀[ܫ]் = ܥ௜௃ ∙ ߝ	∗ [ூ]೅/௄೔௜ ∙
ଵ
௄೔ ∙ ݀[ܫ]்     (Eq. 5) 
If we evaluate this equation at an infinitely small inhibitor concentration, d[I]T can be replaced by 
[I]T. [I]T relates to the inhibitor concentration in the serum [I]S through a partition coefficient PI = 
[I]T/[I]S, which depends on the uptake of the drug into the target cell. This leads to:     
݀ܬ ܬ⁄ = ܥ௜௃ ∙ ߝ	∗ [ூ]೅/௄೔௜ ∙
ଵ
௄೔ ∙ ூܲ ∙ [ܫ]ௌ       (Eq. 6) 
In Eq. 6 the flux control coefficient ܥ௜௃quantifies the extent to which a change in activity of the target 
enzyme i affects the steady-state flux J, i.e. the extent to which an enzyme limits the flux. The flux 
control coefficient involves adaptation of the entire pathway through changes in metabolite 
concentrations. The control coefficient is therefore a property of the entire metabolic network. The 
elasticity coefficient *ߝ[ூ]೅/௄೔௜  quantifies the direct sensitivity of the target enzyme towards a small 
addition of the inhibitor, normalized for the corresponding inhibition constant. Depending on the 
inhibition mechanism, the elasticity coefficient may depend on the metabolite concentrations prior 
to the addition of inhibitor. For instance, the effect of a competitive inhibitor is influenced by the 
concentration of the competing metabolite(s). In this sense, the elasticity coefficient is also part of 
the network response. The mathematical product of the flux control coefficient and the elasticity 
coefficient therefore quantifies the total network-based effect of the drug on the target cell. In 
contrast, the inhibition constant Ki quantifies the structure-based affinity of the target enzyme for 
the inhibitor. The Ki can be optimized by altering the chemical structure of the inhibitor and 
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therefore embodies the structure-based drug effect. The partition coefficient PI of the drug between 
serum and target site measures the pharmacokinetics. Although PI can be optimized through 
structure-based drug design, it also depends on the ADME (Administration-Distribution-Metabolism-
Excretion) network.  
Eq. 6 is valid for both the pathogen and the host. Therefore, the drug selectivity can be defined as 
follows:  
Selectivity ≡ ሺௗ௃ ௃⁄ ሻ೛ೌ೟೓೚೒೐೙ሺௗ௃ ௃⁄ ሻ೓೚ೞ೟ =
ቀ஼೔಻ቁ೛ೌ೟೓೚೒೐೙
ቀ஼೔಻ቁ೓೚ೞ೟
∙
ቀ ఌ	∗ [಺]೅/಼೔
೔ ቁ೛ೌ೟೓೚೒೐೙
ቀ ఌ	∗ [಺]೅/಼೔
೔ ቁ
೓೚ೞ೟
∙ ሺ௄೔ሻ೓೚ೞ೟ሺ௄೔ሻ೛ೌ೟೓೚೒೐೙ ∙
ሺ௉಺ሻ೛ೌ೟೓೚೒೐೙
ሺ௉಺ሻ೓೚ೞ೟  (Eq. 7) 
The serum concentration [I]S drops out of this equation since it is the same for parasite and host. 
From Eq. 7 it follows immediately that network-based determinants of selectivity (ratios of control 
and elasticity coefficients between pathogen and host) are equally important for overall drug 
selectivity as structure-based selectivity (the ratios of inhibition constants) and pharmacokinetics 
(the ratio of partition coefficients).  
Zooming in on the network-based selectivity, we calculated the flux control coefficients and elasticity 
coefficients for putative target enzymes in the glycolysis models of T. brucei and human erythrocytes. 
The parasite-host ratios represent the network-based part of the selectivity (Supplementary Table 
S2). Indeed, the most potent network-based targets identified above (glucose transport and GAPDH) 
rank favorably. According to this MCA-based analysis at low drug concentrations, the glucose 
transporter ranked even better than GAPDH (Supplementary Table S2; final column), showing that 
the conditions may affect the precise ranking. Given that conditions in vivo may be variable, we do 
not think that this subtle difference should favour one target over the other. The underlying ratios of 
flux control and elasticity coefficients (Table S2) enable dissection of the network-based selectivity. In 
the case of the glucose transporter, the network-based selectivity can be attributed to the high ratio 
of flux control coefficients of T. brucei and human erythrocytes (5.8 ∙ 103), while the ratio of elasticity 
coefficients was close to 1 and hence conferred no selectivity. Indeed the flux control coefficient in 
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trypanosomes has previously been shown to be high19, while the erythrocyte transporter seems to 
act close to equilibrium and therefore does not limit the flux 20, 21.   For GAPDH, the flux control 
coefficients also dominated the network-based selectivity. The elasticity coefficients even conferred 
some selective damage to erythrocytes if the inhibitor were to compete with NAD+ and NADH. 
Analogously, all inhibitors of ATP- or ADP-utilizing enzymes suffered from an unfavorable elasticity 
ratio if they were to compete with these cofactors. In general, the elasticity coefficients increase if 
the competing metabolite concentrations are reduced. When considering the possible design of 
drugs that compete with NADH or ATP, their potency might be improved substantially by combining 
them with a drug that inhibits the biosynthesis of these coenzymes. 
From in silico to in vitro: co-cultures of T. brucei with erythrocytes 
To test the model predictions directly, we developed novel co-culture experiments of T. brucei and 
human erythrocytes (schematically depicted in Fig. 3a). We used the T. brucei culture medium (HMI-
9) in which erythrocytes also survived (Supplementary Fig. S2). Fresh erythrocytes were washed and 
resuspended in HMI-9, together with an aliquot from an exponentially growing trypanosome culture. 
As in monocultures 22, T. brucei cell numbers increased exponentially for 24h (Fig. 3b). Growth then 
slowed down until a maximum cell density of 3-4x106 cells/ml was reached; after longer cultivation, 
trypanosome densities started to decrease (Fig. 3b). In the same co-cultures, erythrocyte cell 
densities stayed constant throughout the experiment (Fig. 3c). We note that the trypanosome to 
erythrocyte ratio in our co-cultures (1 in 10-100) is much higher than in patient blood23. This is 
necessary to get reliable cell counts and analyse parasite metabolism (below).  
Pyruvate is secreted as the major end-product of T. brucei glycolysis 22, while erythrocytes metabolize 
glucose to lactate (Fig. 1a). Since neither cell-type has mitochondrial ATP production, these fluxes can 
be used to quantify their ATP production fluxes. To test whether we could use pyruvate production 
as a specific measure of T. brucei glycolysis and lactate production as a specific measure of 
erythrocyte glycolysis, we measured pyruvate production in erythrocyte monocultures and found it 
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to be negligible (Supplementary Fig. S2). The lactate production flux in erythrocyte monocultures was 
two orders of magnitude lower than the pyruvate production flux of T. brucei (see controls in 
Supplementary Fig. S3 and 22). This low lactate production (~1 nmol/min/108 cells) was in agreement 
with measurements in erythrocytes by others 24. Furthermore, addition of 5 mM pyruvate increased 
the lactate production flux of erythrocytes only marginally (Supplementary Fig. S2), suggesting that 
the pyruvate produced by the trypanosomes should not affect lactate production by the 
erythrocytes. We did not detect lactate production in our trypanosome monocultures, which is 
consistent with the absence of a lactate dehydrogenase in the T. brucei genome. Finally, high lactate 
concentrations of up to 6.2 mM did not affect T. brucei growth (Supplementary Fig. S2).  
Glucose-transport inhibition affects T. brucei metabolism selectively in co-cultures 
According to our in silico analysis, the best-ranking drug targets were GAPDH and the glucose 
transporter. Although inhibitors of T. brucei GAPDH exist 13, for a stringent test of the network-based 
selectivity we decided to target glucose transport. This target has the advantage drug uptake is not 
required. We set out to test the model’s prediction that inhibition of glucose transport will affect T. 
brucei glycolysis without harming that of the erythrocytes, even if the inhibitor is not selective for the 
trypanosome transporter THT1 over the erythrocyte transporter GLUT1 25. Erythrocytes also express 
the fructose transporter GLUT5 26, but there is no fructose in the medium. We incubated co-cultures 
with 0-200 μM of phloretin, a competitive inhibitor of glucose transport in both trypanosomes and 
erythrocytes12, 19. Figures 4a-d show growth and metabolite production in one representative 
experiment out of three, and Figs. 4e and 4f summarize the fluxes as determined in all three 
experiments. Phloretin reduced the growth of T. brucei only slightly at 25 μM, but at 100 μM the 
trypanosome numbers decreased after 20h (Fig. 4a). When subjected to 200 μM phloretin, no living 
trypanosomes were found after the 3h time point. In contrast, none of these phloretin 
concentrations affected the erythrocyte density in the co-cultures (Fig. 4b). The trypanosomal 
pyruvate production was also affected strongly by phloretin treatment (Figs. 4c and 4e), with hardly 
any pyruvate production at and above 100 μM phloretin. Phloretin did not inhibit the lactate 
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production by erythrocytes (Fig. 4d and 4f), suggesting that the treatment does not compromise their 
metabolic health. The lactate flux was at the limit of what we could quantify. We could not, however, 
boost the lactate production by using higher erythrocyte cell densities: despite elaborate washing of 
erythrocytes, trypanosomes were unable to grow at erythrocyte densities above 2x107 cells/ml 
(Supplementary Fig. S2). This might be due to the presence of residual amounts of the trypanosome 
lytic factor in the erythrocyte preparations from human blood27. We note that the uninhibited lactate 
flux was lower in co-cultures than in erythrocyte monocultures. The addition of phloretin – even at 
the low concentration of 25 µM, where it hardly affected pyruvate production by trypanosomes – 
increased lactate production in co-cultures up to the level observed in erythrocyte monocultures in 
the absence of phloretin. This suggests that trypanosomes had a negative effect on erythrocyte 
metabolism, which was rectified by inhibition of trypanosome glycolysis. This is not due to the 
pyruvate produced by trypanosomes, since addition of pyruvate did not affect lactate production in 
erythrocyte monocultures (above).   
Glucose-transport inhibition selectively affects T. brucei survival in co-cultures 
Subsequently, we monitored cell growth and survival over a broader phloretin concentration range 
and for two additional glucose-transport inhibitors: cytochalasin B and compound 3361 (Fig. 5a). 
Cytochalasin B is an inhibitor of erythrocyte and trypanosome glucose transport (28 and 
Supplementary Fig. S3). Compound 3361 is a glucose analog that was originally designed against the 
malaria parasite Plasmodium falciparum29, where it was selected because it did not affect the 
erythrocyte transporter GLUT1. Each of these inhibitors reduced trypanosome proliferation in a 
dose-dependent manner without affecting erythrocyte density. All trypanosomes were killed in co-
cultures that were treated with ≥100 μM phloretin, ≥250 μM cytochalasin B or ≥190 μM compound 
3361 (Fig. 5a). Fig. 5b shows microscopy images of control (solvent-treated) co-cultures and co-
cultures treated with 450 μM phloretin for 25h. The latter were entirely cleared of trypanosomes. 
Erythrocytes appeared unaffected, although we cannot draw any conclusions on erythrocyte health 
from these pictures. In separate experiments we showed that at this phloretin concentration, lactate 
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production of erythrocytes in unaffected (Supplementary Fig. S3). As a positive control to show that 
metabolic inhibitors can affect erythrocyte survival we treated erythrocytes with 2-phosphoglycolate, 
an inhibitor of erythrocyte pyruvate kinase 30 (Supplementary Fig. S3). The highest concentration (24 
mM) killed all erythrocytes within one day, in agreement with the known detrimental effect of 
insufficient pyruvate kinase levels in erythrocytes 14.    
For phloretin and cytochalasin B, we confirmed that concentrations that were lethal to trypanosomes 
(Fig. 5a), did not affect lactate production flux in erythrocyte monocultures (Supplementary Fig. S3). 
Since phloretin and cytochalasin B have been reported to be more active against the erythrocyte 
glucose transporter GLUT1 than against the T. brucei counterpart THT1 (Fig 5A and 28), our results are 
a prominent example of how a strong network-based selectivity can even overrule unfavorable 
selectivity at the molecular level (cf. Eq. 7). 
The broader perspective: phloretin and cytochalasin B only moderately affect neurons and 
hepatocytes, but strongly affect Plasmodium falciparum  
We did a pilot study to test the systemic effect of phloretin on T. brucei in mice infected with T. 
brucei. However, despite initial clearing of the infection (Supplementary Fig. S5), validating our 
modelling results, phloretin had no lasting effect due to its poor pharmacokinetics (31 and 
Supplementary Table S3).  
Two host cell types that are expected to be sensitive to glucose-transport inhibition are neuronal 
cells, the brain being the major consumer of glucose in the body, and hepatocytes, since the liver 
plays a crucial role in whole-body glucose homeostasis. We therefore tested the effect of the 
inhibitors on neuronal cell line HT-22 and primary rat hepatocytes. Phloretin, but not cytochalasin B, 
had a strong effect on the oxygen consumption rate (OCR) of HT-22 cells (Fig 6a). Indeed, inhibition 
of mitochondrial respiration is a known side effect of phloretin 32, making this inhibitor less suitable 
for the testing of glucose transport inhibition in neurons and hepatocytes. This side effect was 
irrelevant in erythrocytes, which do not contain mitochondria. Subsequently, the effect on glycolytic 
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flux  was measured as extracellular acidification rate (ECAR) in the presence of the oxidative 
phosphorylation inhibitor oligomycin. 125 µM  of phloretin, a dosage sufficient to kill trypanosomes 
(cf. Fig 5a), inhibited the glycolytic flux in HT-22 cells by 25% and 250 µM cytochalasin B by 50% (Fig 
6b). At similar concentrations phloretin and cytochalasin B did not kill HT-22 cells at all (Fig 6c), 
showing clear selectivity of the drugs against trypanosomes versus HT-22 cells. Hydrogen peroxide 
was added as a positive control and clearly triggered apoptosis in HT-22 cells (Fig 6c). 
To investigate how glucose transport inhibition affects liver cells, we first simulated glycolysis with a 
comprehensive kinetic model of human hepatocytes, which includes hormonal effects and glycogen 
content. Earlier analyses of this model had shown that the hepatic glucose transporter GLUT2 
exerted no flux control over a range of glucose concentrations 33, suggesting that hepatocytes are not 
vulnerable to glucose transport inhibition. Using the same model, we calculated that hepatocyte 
glucose production and glycolytic flux where hardly affected in the range of inhibitor concentrations 
that kill trypanosomes (Supplementary Fig S6). As an in vitro test we monitored the change in cell 
impedance of primary hepatocyte cultures over 20 hours in the absence or presence of glucose 
transport inhibitors (Fig. 6d). Impedance is caused by adherence of cells to the bottom and used as a 
proxy for cell proliferation and shape. 60% impedance was maintained during treatment with 100 
µM of phloretin (a concentration that kills trypanosomes within a day (Fig 5a)), and 70% in the 
presence of cytochalasin B. These results show that, although hepatocyte viability is clearly 
somewhat affected by these inhibitors, glucose transport inhibition has network-selectivity against 
trypanosomes also compared to hepatocytes.   
Finally, we tested the effect of glucose transport inhibition on the malaria parasite Plasmodium 
falciparum. In contrast to T. brucei, P. falciparum is an intracellular parasite that invades 
erythrocytes. Recently, computational modelling suggested that also in Plasmodium trophozoites 
(the blood stage) the glucose transporter is the preferred network-based target and this was 
confirmed in isolated trophozoites 34. In contrast to T. brucei, the malaria parasite produces lactate. 
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This lactate production is up to 100-fold higher than that of its host cell 35. When Plasmodium-
infected erythrocytes were subjected to cytochalasin B, a strong and dose-dependent reduction of 
the lactate production flux was found (Fig 6e). Since the lactate production flux of infected 
erythrocytes is dominated by the contribution of the intracellular parasites, this indicates that 
glucose transport inhibition is also prominent target in Plasmodium when residing in its host cell. 
Discussion 
In this paper we have shown – both theoretically and experimentally – how it is possible to kill a 
pathogen selectively, with minimal effect on the host, by targeting a metabolic pathway that is 
essential for host and pathogen alike. Although targeting a unique pathogen protein may open 
powerful avenues for selective inhibition, uniqueness itself does not make it a potent drug target 
against the pathogen. A drug against a target that is not essential for survival of the pathogen will not 
kill it. Furthermore, if near-complete inhibition of the unique target would be needed in order to kill 
the pathogen, the required inhibitor dosage would increase the risk of off-target side-effects to the 
host. Essentiality of the target pathway and relatively high flux control of the specific target in the 
parasite thus need to be the first criteria for potential targets. Identification of a pathogen-specific 
target that meets these criteria enables design of drugs with strong molecular selectivity.  
Our study shows that very promising targets can exist outside the realm of the unique proteins. 
Glycolysis is an essential pathway for bloodstream-form Trypanosoma brucei and a moderate 
inhibition (50%) is sufficient to kill the parasite 12. This makes it a promising target pathway for 
antitrypanosomal drugs. However, T. brucei glycolysis does not contain unique parasitic proteins 
(although some are evolutionary and structurally distant from their human counterparts (see 13 and 
references therein). Moreover, glycolysis is also essential for many human cell types. We have 
demonstrated that this need not be an obstacle: quantitative differences between trypanosome and 
erythrocyte lead to strong network-based selectivity. This network-based selectivity depends equally 
on the flux control exerted by the target enzyme and on the in vivo elasticity (sensitivity) of the 
17 
 
target enzyme towards the drug. The latter depends on the degree of saturation of the enzyme with 
its substrates and products. The generality of this principle makes it applicable to any disease in 
which specific cell types must be targeted selectively. We have further shown that this network-
based selectivity is just as important as selectivity based on the structure of the molecular target (Eq. 
7).  
Here we validated model simulations for the network-selectivity of glucose transport inhibition 
towards T. brucei over erythrocytes. We also showed that inhibition of pyruvate kinase is indeed 
detrimental to erythrocytes, as predicted by the corresponding model. With respect to some other 
targets, both kinetic models had previously been validated extensively. For the T. brucei model, apart 
from the glucose transporter itself19, the effect of reduction of various other enzyme activities had 
been validated by RNAi knockdowns9. The erythrocyte model has been validated by comparing 
predictions to clinical data of inborn enzyme deficiencies36.  
Drug design that is mechanistic and structure-based will often lead to the development of 
competitive inhibitors. Several drugs in clinical use are competitive enzyme inhibitors, such as the 
phosphodiesterase inhibitor Viagra and the bcl-abl kinase inhibitor Gleevec17. This was why we 
focused on competitive inhibitors first. The values observed for the elasticity coefficients suggest, 
however, that other modes of drug action may lead to a different network-based selectivity. For 
instance, in the computer models a competitive inhibitor of aldolase was calculated to be somewhat 
selective against erythrocytes (Supplementary Fig. S1) due to a lower concentration of the competing 
substrate fructose-1,6-bisphosphate (0.0010 mM in erythrocytes versus 13 mM in trypanosomes). 
This caused a higher elasticity in the erythrocyte (*ߝ[ூ]/௄೔௔௟ௗ௢௟௔௦௘  was -6.7x10-2 in erythrocytes 
versus -3.0∙10-3 in trypanosomes), conferring a 22-fold selectivity towards the erythrocyte enzyme. 
Since uncompetitive inhibitors become more effective at higher substrate concentrations 7, 
uncompetitive inhibitors of aldolase should be selective against trypanosomes, which we confirmed 
computationally (Supplementary Fig. S4). 
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Each host cell type has its own characteristic metabolic network. Indeed, our in vitro tests on primary 
neurons and liver cells show that these cell types are more affected by glucose transport inhibition 
than erythrocytes, but still markedly less than trypanosomes. With respect to toxicity for these cells 
it may therefore be useful to enhance the network selectivity with  molecular selectivity. Molecular 
side-effects against the hepatocyte and brain transporters GLUT2 and GLUT3, respectively, should 
then be more important to consider than those against the erythrocyte transporter GLUT1. In 
addition, a chronic and severe deficiency of GLUT1 is known to affect the brain, since this transporter 
is also essential for glucose uptake through the blood-brain barrier 37, suggesting that a combined 
network- and structure-based approach will also for GLUT1 be the most effective. Realistically, 
however, a more comprehensive analysis of different host cell types will be needed. Although such 
an endeavor may be challenging, it is warranted by the fact that glycolysis is a promising target not 
only in trypanosomes, but also in various parasites including Plasmodium, as well as in certain 
tumors. Along these lines, we showed that glucose transport inhibition strongly affected metabolism 
in Plasmodium-infected erythrocytes. A characterization of host-cell network sensitivity can be 
reused for all these applications. In this light our results should be viewed as proof of principle that 
network selectivity is possible. Where necessary and possible, selectivity may be increased by 
exploiting structural differences between pathogen and host targets, eliciting synergy between 
network- and structure-based selectivity (cf. Eq. 7). The results obtained with compound 3361, which 
was selected for absence of an effect against the erythrocyte glucose transporter GLUT1 29, suggest 
that the latter is feasible. This development may well be boosted by the elucidation of the crystal 
structure of GLUT1 38.  
A strong advantage of the selection of drug targets from a pathway operating in both pathogen and 
host is that it allows compound re-purposing. For instance, anticancer compounds that were 
discarded because of their limited effect on tumors, can now be re-tested for an effect on the high-
ranking enzymes within trypanosome glycolysis (Fig 1d). 
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The same approach will be crucial for identifying selective drug targets for the treatment of certain 
types of cancer. Since cancer cells originate from their host, their genome only encodes pathways 
that also operate in healthy cells. Upregulated and altered metabolism has been re-recognized as a 
hallmark of cancer and is back in focus as a target for anticancer drugs 39. Differences in gene 
expression levels between tumor cells and healthy cells may be exploited to optimize network-based 
selectivity. We recommend that the strategy described in this paper be implemented in the 
development of potent drugs that cause minimal collateral damage to host tissues.   
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Methods 
Computer models and code availability 
For T. brucei glycolysis, we used the model version C from Kerkhoven et al.15 (availabe as a 
supplement to this reference), i.e. the model that contains the glycosomal ribokinase, but without 
the fructose branch.  For the erythrocyte model by Holzhütter 16 we used the curated SMBL file from 
BioModels 40. The steady-state fluxes of this model were the same as reported in Table 1 of 16.  
Simulations were carried out in the program COPASI (version 4.11; build 65) 41. The rate through the 
ATP utilization (ATPase) reaction was monitored as the output flux. At steady state this rate equals 
the net ATP production flux. 
Inhibitors 
Phloretin was purchased from Sigma and Cytochalasin B from Serva. They were dissolved in 70% 
ethanol. Compound 3361 (3-O-[undecyl-10-en]-1-yl-D-glucose)	29 was a kind gift from Dr. H. Staines 
and Dr. S. Krishna and was dissolved in DMSO. Control cultures were treated with the same amount 
of solvent as the corresponding inhibitor-treated cultures. The final solvent concentration in the 
cultures was ≤ 0.35% (v/v) ethanol for phloretin experiments, ≤ 0.7% ethanol (v/v) for cytochalasin B 
experiments and ≤ 0.2% (v/v) DMSO for experiments with compound 3361, unless indicated 
otherwise.  
Human blood 
5 mL blood was drawn from a single subject by venipuncture into a Becton Dickinson Vacutainer 
containing heparin. A 20-200 μl aliquot of this, containing predominantly erythrocytes, was washed 
twice in more than 10 volumes of sterile isotonic buffer (25 mM HEPES, 1 mM NaH2PO4, 115 mM 
NaCl, 10 mM KCl, 2 mM MgCl2, pH = 7.5; 24) and taken up in HMI-9, the culture medium for 
trypanosomes. Erythrocyte densities were determined manually by counting in a Bürker 
hemocytometer. We submitted our study to the medical ethics committee of the VUmc who found  
no ethical issues attached to this research. 
21 
 
T. brucei cultivation 
Monomorphic bloodstream-form T. brucei strain 427 (cell line 449) 42 (obtained from Prof. P.  
Michels, then at Université Catholique de Louvain, Brussels) was cultured in HMI-9 supplemented 
with 10% fetal calf serum (Invitrogen) and 0.2 μg/ml phleomycin (Cayla) in a water-saturated 
incubator with 5% CO2 at 37°C as described previously 42. Cell densities were determined manually by 
counting in a Bürker hemocytometer. Only motile trypanosomes were counted. Cultures were 
maintained in exponential growth through dilution (i.e. between 1x105 and 3x106 cells/ml). The cell 
line was not authenticated and cells have not been tested for mycoplasma contamination. 
Co-cultures of human blood and T. brucei 
The erythrocytes were resuspended in HMI-9 medium, inoculated with T. brucei in HMI-9 medium 
and incubated as above. During the experiments glucose was not depleted. 
Metabolite measurement 
Metabolite samples were taken from the culture, instantly quenched by addition of 1/10 volume of 
ice-cold 35% (v/v) perchloric acid (PCA). PCA-treated samples were snap-frozen in N2 (l) and stored at 
-80°C. After thawing, the samples were neutralized by addition of 1/10 volume of an ice-cold solution 
of 5 M KOH in 0.2 M MOPS. After 10 minutes incubation on ice, the precipitated proteins were 
removed by centrifugation. Enzymatic assays for pyruvate 43 and lactate 44 were performed on the 
supernatant using a VITALAB Selectra E chemistry analyzer (INstruchemie, Delfzijl, The Netherlands). 
Time points were chosen such that the increase of both pyruvate and lactate in time could be 
quantified. 
Flux calculations 
Pyruvate production fluxes were calculated over the first 20-24h as described previously12 at 
phloretin concentrations up to 50 µM, the flux was calculated by multiplying the specific growth rate 
with the slope of the plot of pyruvate concentration versus cell density. At higher concentrations, 
when growth was severely affected, the slope of the pyruvate concentration against time was 
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divided by the average trypanosome cell density. Lactate production fluxes were calculated over 50h 
by dividing the slope of the lactate concentration versus time by the erythrocyte cell density (which 
remained constant). 
Microscopy 
Smears of co-cultures were made on glass slides. Cells were fixed for 30 seconds in methanol and 
subsequently stained for 25 minutes in a 5% Giemsa solution in a phosphate-based buffer (6 mM 
KH2PO4, 4.3 mM Na2HPO4∙H2O). Slides were washed three times with tap water and dried in air. 
Images were acquired using a Leica DM-LB microscope equipped with Leica Application Suite 3.8.0 
build 818. 
Cell Culture of neuronal HT-22 Cells 
HT-22 cells, which were derived from immortalized hippocampal neurons and obtained from Dr. 
Schubert, Salk Institute, San Diego, were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, 
Karlsruhe, Germany) supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, 
100 µg/ml streptomycin, and 2 mM glutamine. The cell line was not authenticated but was tested to 
be mycoplasma-free. 
Measurements of Oxygen Consumption Rate (OCR) and Extracellular acidification rate (ECAR) 
For OCR and ECAR measurements we used an XF96 Extracellular Flux Analyzer (Seahorse Bioscience, 
North Billerica, MA), which directly records the OCR in cells that remain attached to the culture plate 
by using calibrated optical sensors. The OCR/ECAR recordings were carried out as previously 
described with minor modifications 45.  
Cell death analysis 
Cells were seeded in 24-well plates (60,000 cells/well) for 24 h and challenged with different 
concentrations of phloretin and cytochalasin B. Cell viability was quantified after 5 h by AVPI staining 
23 
 
and subsequent FACS-analysis. Cells were harvested by using Trypsin/EDTA, washed once in PBS and 
stained according to the manufacturer’s protocol (Annexin-V-FITC Detection Kit, PromoKine, 
Promocell, Heidelberg, Germany). Afterwards stained cells were analyzed by FACS-analysis. Annexin-
V-FITC was excited at 488 nm and emission was detected through a 530 ± 40 nm band pass filter. 
Propidium iodide was excited at 488 nm and fluorescence emission was detected using a 680 ± 30 
nm band pass filter. At least 10,000 gated events per sample were analyzed.  
Isolation of primary rat hepatocytes  
Hepatocytes were isolated from male Wistar rats (220-250g) by a two-step collagenase perfusion 
procedure as described previously46. Experiments were performed following the guidelines of the 
local Committee for Care and Use of Laboratory Animals of the University of Groningen. Cell viability 
was determined by trypan blue staining and exceeded 85%. 
Real-time monitoring of primary hepatocyte viability  
104 freshly isolated primary hepatocytes were plated per well of 0.20 cm2 on xCELLigence E plates 
with interdigitated gold microelectrodes to constantly record cell confluency by impedance 
measurement, according to manufacturer’s instructions47. The primary hepatocytes were grown in 
William’s E medium (Life Technologies Ltd; Breda, The Netherlands) supplemented with 50 µg/mL 
gentamycin (Life Technologies Ltd) and penicillin-streptomycin-fungizone (Lonza, Verviers, Belgium). 
During the attachment period (4h) 50 nmol/L dexamethasone (Sigma, St Louis, USA) and 5% fetal calf 
serum (Life Technologies Ltd) were added to the medium. Cells were cultured in a humidified 
incubator at 37 °C and 5% CO2. Treatment was started 4 h after attachment. Results were recorded 
and analyzed by RTCA Software. Cell index at t=20h was compared to that at t=0h (addition of 
compound) and normalized to the ethanol-control (0.7% v/v). 
More information can be found in the supplemental methods 
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Figure legends 
Figure 1 Simulating competitive inhibition of trypanosome glycolysis 
(a) Outline of glycolysis and the reactions included in the in silico models. Circles show the enzymes. 
Blue parts are specific to bloodstream-form T. brucei and red parts are erythrocyte specific. The 
boxed and colored metabolites are secreted. Note that BSF T. brucei only produces substantial 
amounts of glycerol under anaerobic conditions 48 and that in T. brucei the enzymes from HXK to PGK 
are sequestered in specialized peroxisomes, called glycosomes. ATP util: ATP utilization; GlcT: glucose 
transport; HXK: hexokinase; PGI: phosphoglucoisomerase; PFK: phosphofructokinase; ALD: aldolase; 
TPI: triose-phosphate isomerase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; PGK: 
phosphoglycerate kinase; PGAM: phosphoglycerate mutase; ENO: enolase; PYK: pyruvate kinase; 
PPP: pentose phosphate pathway (present in detail in both models); G6P: glucose 6-phosphate; F6P: 
fructose 6-phosphate; F16BP: fructose 1,6-bisphosphate; DHAP: dihydroxyacetone phosphate; GAP: 
glyceraldehyde 3-phosphate; 13BPGA: 1,3-bisphosphoglycerate; 3PGA: 3-phosphoglycerate; 2PGA: 2-
phosphoglycerate; PEP: phosphoenolpyruvate. (b) Flowchart of the computational approach (c) The 
steady-state ATP production flux in the T. brucei model was simulated in the absence and presence 
of competitive inhibitors of a specific enzyme by increasing [I]/Ki. The simulated inhibitor competed 
with the indicated substrate and the corresponding product. The dashed line indicates 90% flux 
inhibition. Glc: glucose. (d) For each glycolytic enzyme, inhibition of the ATP synthesis flux in T. brucei 
was simulated for an inhibitor competitive with the substrate indicated in yellow (and its product; 
see Table S1), and ranked on the basis of the amount of [I]/Ki needed to inhibit by 90%. The HXK 
inhibitor affected both the cytosolic and the glycosomal HXK fraction. Glc: glucose. 
See also Supplementary Fig S1  
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Figure 2 Simulating the differential inhibition of T. brucei and erythrocyte glycolysis 
(a-d) Competitive inhibition was simulated in the T. brucei (blue, solid line) and erythrocyte glycolysis 
models (red, dashed line). The target enzyme and the competing substrate are indicated above each 
panel. Abbreviations as in Fig. 1. (e) At the [I]/Ki value that inhibited the flux of T. brucei by 90% (Fig 
1d), we calculated the residual glycolytic flux in the erythrocyte model. The higher the residual flux 
the fewer side effects can be expected.  
See also Supplementary table S1, S2  and Figs S1 and S4 
Figure 3 Co-cultures of T. brucei and erythrocytes 
(a) Schematic representation of the co-cultures of T. brucei (in blue) and erythrocytes (in red) in HMI-
9 medium. The cell density of trypanosomes (b) and erythrocytes (c) are shown for three 
independent co-cultures (each given a different color and symbol). These are the control cultures for 
the experiments shown in Fig. 4. 
See also Supplementary Fig. S3 
Figure 4 Effects of glucose-transport inhibition on co-cultures of T. brucei and erythrocytes 
Co-cultures were treated with various concentrations of phloretin in 0.14% ethanol or with 0.14% 
ethanol only (control):  ethanol control,  25 μM,  100 μM,  200 μM phloretin. Ethanol was 
shown not affect metabolism in the co-cultures (see Fig S2 and 12). (a) Cell density of trypanosomes in 
the co-cultures. The culture treated with 100 μM phloretin had no live trypanosomes at 47h, and for 
200 μM phloretin trypanosomes were dead at the 21h time point. (b) Cell density of erythrocytes in 
the co-cultures. (c) Concentration of pyruvate in the co-cultures. (d) Concentration of lactate (the 
metabolic end-product of erythrocytes) in the co-cultures. (e) Pyruvate fluxes were calculated over 
the first 20-24h (the exponential growth phase for trypanosomes in the control cultures). Each color 
denotes an independent experiment. The red data points are from the same experiment as shown in 
panel C and D. Fluxes are displayed relative to the flux in the corresponding control co-culture. The 
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dashed line represents a linear fit through all data points (R2= 0.73). A linear fit without the 200 μM 
point and the outlier at 100 μM is given in Supplementary Figure S3 and has an R2=0.86  (f) Lactate 
production fluxes were calculated over 50h. Each color denotes an independent experiment and the 
color coding corresponds to that of Fig. 4e. Fluxes are relative to the flux in the corresponding control 
co-culture. 
See also Supplementary Figs S2 and S3 
Figure 5 Differential survival in co-cultures treated with three different glucose-transport inhibitors 
(a) Cells in the co-cultures were counted at the start of the experiment (day 0) and on day 1 (after 25-
28 hours), and the ratio was plotted. Published inhibition constants (Ki values) are indicated below 
the graph for the trypanosome glucose transporter (THT1)19, 49 and the erythrocyte transport (GLUT1) 
50, 51, 52. N.d. = not previously determined. The left axis shows the ratio for the trypanosomes in the 
co-culture; the right axis shows the ratio for the human erythrocytes in the co-cultures. Each 
concentration of inhibitor was tested at least twice on independent cultures. Each graph shows the 
combined results of at least two different experiments, resulting in ≥4 independent controls. For 
phloretin: Cell densities at the start were 2-7x105/ml for T. brucei, and ~5x106 cells/ml for 
erythrocytes. All co-cultures were treated with ≤0.1% v/v ethanol (solvent). For cytochalasin B: Cell 
densities at the start were 1-4x105/ml for T. brucei, and ~1x107 cells/ml for erythrocytes. Co-cultures 
were treated with ≤0.7% v/v ethanol (solvent). Only the co-culture that was treated with 500 μM 
cytochalasin B had a concentration of 1.4% ethanol due to the maximum solubility of cytochalasin B. 
This ethanol concentration had a minimal effect on the T. brucei growth rate. For compound 3361: 
Cell densities at the start were 1.5x105/ml for T. brucei, and 0.5-1x106 cells/ml for erythrocytes. Co-
cultures were treated with ≤0.2% v/v dimethyl sulfoxide (solvent). Asterisks below the graphs 
indicate for trypanosomes at which concentrations the mean of the data-points differs from the 
mean of the controls with a P-value < 0.05 in a two-tailed t-test assuming unequal variances.  (b) 
Microscope images of Giemsa-stained smears of a co-culture before treatment with phloretin (t=0) 
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and two co-cultures treated with solvent (EtOH) or 450 μM of phloretin for 25 hours. Asterisks mark 
the trypanosomes in the cultures. The experiments in this figure were performed independently of 
the metabolic experiments shown in Fig. 4. Supplementary Figure S3 shows that at these inhibitor 
concentrations the lactate production flux by erythrocytes is unaltered compared to that of 
uninhibited erythrocytes. 
See also Supplementary Figs S3 and S5 
Figure 6 Effects of phloretin and cytochalasin B on neuronal cells, hepatocytes and malaria-infected 
erythrocytes 
(a) Oxygen consumption rate (OCR) in HT22 neuronal cells after treatment with phloretin ((n=1, but 
based on 6 technical replicates of which the standard deviation was 0.9-1.6%) and cytochalasin B 
(n=2; two biological replicates with 3 technical replicates each – shown is the mean with standard 
deviation compared to vehicle-control compared to vehicle-control). Raw data before and after 
inhibition is shown in Supplementary Fig. S7 (b) Extracellular acidification rate (ECAR) in neuronal 
HT22 cells after oligomycin treatment following treatment with phloretin (n=1, but based on 6 
technical replicates of which the standard deviation was 2.5-5%)) or cytochalasin B (n=2; two 
biological replicates with 6 technical replicates each – shown is the mean with standard deviation 
compared to vehicle-control). (c) Cell death assay on neuronal HT22 cells after 5 hours of indicated 
treatment. Healthy cells exclude propidium iodide (PI) and only apoptotic cells are positive for 
AnnexinV (AnV+). Shown is the mean and standard deviation of three incubations. 900 µM H2O2 is 
known to evoke apoptosis and is a positive control (d)  Survival based on cell impedance 
measurements of primary rat hepatocytes after 20 hours of treatment with phloretin or Cytochalasin 
B compared to vehicle control. Shown is the mean of two biological replicates with standard 
deviation. (e) Lactate production flux in erythrocytes infected with Plasmodium falciparum enriched 
for parasites in the trophozoite stage. The lactate produced was followed over 1 hour (5 time points) 
in the absence or presence of cytochalasin B. The uninhibited flux equals 0.069 
fmol/min/erythrocyte. Each datapoint is based on at least two biological replicates and three 
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technical replicates; error bars show standard error of the mean. The dashed line is a fitted 
exponential decay function. 
See also Supplementary Figs S6 and S8  
 






